{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:55:58Z","timestamp":1790492158253,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["ANRS-COV13 \/ EMuLCOVID-19"],"award-info":[{"award-number":["ANRS-COV13 \/ EMuLCOVID-19"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000036","name":"Institute of Population and Public Health","doi-asserted-by":"publisher","award":["CIHR-IRSC:0579001152"],"award-info":[{"award-number":["CIHR-IRSC:0579001152"]}],"id":[{"id":"10.13039\/501100000036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012016","name":"Institut National de Sant\u00e9 Publique du Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014131","name":"McGill University Health Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The world has high hopes of vaccination against COVID-19 to protect the population, boost economies and return to normal life. Vaccination programmes are being rolled out in high income countries, but the pandemic continues to progress in many low-and middle-income countries (LMICs) despite implementation of strict hygiene measures. We aim to present a comprehensive research protocol that will generate epidemiological, sociological and anthropological data about the COVID-19 epidemic in Burkina Faso, a landlocked country in West Africa with scarce resources.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We will perform a multidisciplinary research using mixed methods in the two main cities in Burkina Faso (Ouagadougou and Bobo-Dioulasso). Data will be collected in the general population and in COVID-19 patients, caregivers and health care professionals in reference care centers: (i) to determine cumulative incidence of SARS-CoV-2 infection in the Burkinabe population using blood samples collected from randomly selected households according to the WHO-recommended protocol; (ii) develop a score to predict severe complications of COVID-19 in persons infected with SARS-CoV-2 using retrospective and prospective data; (iii) perform semi-structured interviews and direct observation on site, to describe and analyze the healthcare pathways and experiences of patients with COVID-19 attending reference care centers, and to identify the perceptions, acceptability and application of preventive strategies among the population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study will generate comprehensive data that will contribute to improving COVID-19 response strategies in Burkina Faso. The lessons learned from the management of this epidemic may serve as examples to the country authorities to better design preventive strategies in the case of future epidemics or pandemics.<\/jats:p>\n                <jats:p>The protocol was approved by the Ministry for Health (N\u00b0 2020-00952\/MS\/CAB\/INSP\/CM) and the Health Research Ethics Committee in Burkina Faso (N\u00b0 2020-8-140).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06543-4","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T08:31:45Z","timestamp":1630657905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["COVID-19 epidemiological, sociological and anthropological investigation: study protocol for a multidisciplinary mixed methods research in Burkina Faso"],"prefix":"10.1186","volume":"21","author":[{"given":"Isidore Tiandiogo","family":"Traor\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8224-5543","authenticated-orcid":false,"given":"Samiratou","family":"Ouedraogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dramane","family":"Kania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firmin Nongodo","family":"Kabor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blahima","family":"Konat\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"M\u00e9dah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Badolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"de Rekeneire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane Mamguem","family":"Kamga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armel","family":"Poda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud Eric","family":"Diendere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boukary","family":"Ou\u00e9draogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperance","family":"Ou\u00e9draogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumar","family":"Billa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halidou","family":"Tinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienhan Sandrine","family":"Dabakuyo-Yonli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"6543_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa2001316.","journal-title":"N Engl J Med"},{"issue":"7798","key":"6543_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265\u20139.","journal-title":"Nature"},{"issue":"3","key":"6543_CR3","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","volume":"55","author":"CC Bon-Lai","year":"2020","unstructured":"Bon-Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.","journal-title":"Int J Antimicrob Agents."},{"key":"6543_CR4","unstructured":"World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 Accessed 27 Apr 2021."},{"key":"6543_CR5","unstructured":"World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report \u2013 80. https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200409-sitrep-80-covid-19.pdf?sfvrsn=1b685d64_6 Accessed 13 Mar 2020."},{"key":"6543_CR6","unstructured":"Minist\u00e8re de la sant\u00e9 du Burkina Faso. Rapport de situation sur l\u2019\u00e9pid\u00e9mie de la maladie \u00e0 Coronavirus (COVID-19) au Burkina Faso. 10 juin 2020. https:\/\/www.humanitarianresponse.info\/sites\/www.humanitarianresponse.info\/files\/documents\/files\/sitrep_ndeg_103.pdf Accessed 21 Mar 2020."},{"key":"6543_CR7","unstructured":"World Health Organization. Daily distribution of cases in the WHO African Region. https:\/\/www.afro.who.int\/healthtopics\/coronavirus-covid-19 Accessed 13 Apr 2021."},{"key":"6543_CR8","unstructured":"National Institutes of Health. NIH clinical trial of hydroxychloroquine, a potential therapy for COVID-19, begins. 2020. https:\/\/www.nih.gov\/news-events\/news-releases\/nih-clinical-trial-hydroxychloroquine-potential-therapy-covid-19-begins Accessed 09 May 2020."},{"key":"6543_CR9","unstructured":"World Health Organization. Draft landscape of Covid-19 candidate vaccines. March20, 2020. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines. Accessed 13 April 2021."},{"key":"6543_CR10","unstructured":"World Health Organization. A coordinated global research roadmap. 2020. https:\/\/www.who.int\/publications\/m\/item\/a-coordinated-global-research-roadmap. Accessed 13 Apr 2021."},{"key":"6543_CR11","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"1","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;1:105949.","journal-title":"Int J Antimicrob Agents."},{"issue":"1","key":"6543_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","volume":"14","author":"J Gao","year":"2020","unstructured":"Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72\u20133.","journal-title":"Biosci Trends"},{"key":"6543_CR13","unstructured":"Communiqu\u00e9 \u2013 salle de presse Inserm. Covid-19 Lancement d\u2019un essai clinique europ\u00e9en contre l\u2019infection \u00e0 SARS-CoV-2. https:\/\/presse.inserm.fr\/lancement-dun-essai-clinique-europeen-contre-le-covid-19\/38737\/ Accessed 07 Apr 2021."},{"key":"6543_CR14","unstructured":"Organisation Mondiale de la Sant\u00e9. L\u2019essai clinique Solidarity produit en un temps record des preuves concluantes sur l\u2019efficacit\u00e9 des m\u00e9dicaments r\u00e9affect\u00e9s au traitement de la COVID-19. 15 octobre 2020 Communiqu\u00e9 de presse. https:\/\/www.who.int\/fr\/news\/item\/15-10-2020-solidarity-therapeutics-trial-produces-conclusive-evidence-on-the-effectiveness-of-repurposed-drugs-for-covid-19-in-record-time April 13 Dec 2021."},{"key":"6543_CR15","unstructured":"Minist\u00e8re de l\u2019enseignement sup\u00e9rieur, de la recherche scientifique et de l\u2019innovation du Burkina Faso. Communiqu\u00e9 de presse sur la contribution de la recherche scientifique \u00e0 la lutte contre l\u2019infection \u00e0 SARS-CoV-2. 26 mars 2020."},{"key":"6543_CR16","unstructured":"Businesswire. Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints. November 18, 2020. https:\/\/www.businesswire.com\/news\/home\/20201118005595\/en\/ Accessed 13 Apr 2021."},{"key":"6543_CR17","unstructured":"AstraZeneca PLC. COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials. https:\/\/www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2021\/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html. Accessed 15 July 2021."},{"key":"6543_CR18","doi-asserted-by":"crossref","unstructured":"Oliver SE, Gargano JW, Scobie H, et al. The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Janssen COVID-19 Vaccine \u2014 United States, February 2021. MMWR Morb Mortal Wkly Rep 2021;70:329\u2013332. https:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7009e4.htm?s_cid=mm7009e4_w#suggestedcitation. Accessed 15 July 2021.","DOI":"10.15585\/mmwr.mm7009e4"},{"key":"6543_CR19","unstructured":"Moderna. Moderna\u2019s Work on a COVID-19 Vaccine Candidate. https:\/\/www.modernatx.com\/modernas-work-potential-vaccine-against-covid-19 Accessed 07 Dec 2021."},{"issue":"3","key":"6543_CR20","doi-asserted-by":"publisher","first-page":"2000045","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","volume":"25","author":"VM Corman","year":"2020","unstructured":"Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019- nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045.","journal-title":"Euro Surveill"},{"key":"6543_CR21","unstructured":"World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. WHO reference number: WHO\/COVID-19\/laboratory\/2020.5. https:\/\/www.who.int\/publications-detail\/laboratory-testing-for-2019-novel-coronavirusin-suspected-human-cases-20200117 Accessed 13 Apr 2021."},{"key":"6543_CR22","unstructured":"Organisation Mondiale de la sant\u00e9. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/332188\/WHO-2019-nCoV-Seroepidemiology-2020.2-eng.pdf?sequence=1&isAllowed=y Accessed 13 Apr 2021."},{"key":"6543_CR23","doi-asserted-by":"crossref","unstructured":"Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020: ciaa344.","DOI":"10.1093\/cid\/ciaa344"},{"key":"6543_CR24","doi-asserted-by":"publisher","unstructured":"Amanat F, Nguyen T, Chromikova V et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. https:\/\/www.medrxiv.org\/content\/. https:\/\/doi.org\/10.1101\/2020.03.17.20037713v1 Accessed 15 Apr 2021.","DOI":"10.1101\/2020.03.17.20037713v1"},{"key":"6543_CR25","doi-asserted-by":"crossref","unstructured":"Zhou Y, Zhang Z, Tian J, Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. Ann Palliat Med. 2020.","DOI":"10.21037\/apm.2020.03.26"},{"issue":"7","key":"6543_CR26","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","volume":"180","author":"C Wu","year":"2020","unstructured":"Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China JAMA Intern Med. 2020;180(7):934\u201343. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0994.","journal-title":"China JAMA Intern Med"},{"key":"6543_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4000\/civilisations.748","volume":"52\u20131","author":"D Berlinier","year":"2004","unstructured":"Berlinier D. Perception des fi\u00e8vres h\u00e9morragiques \u00e0 virus Ebola sur la fronti\u00e8re congogabonaise. Civilisations. 2004;52\u20131:117\u201320.","journal-title":"Civilisations"},{"key":"6543_CR28","first-page":"1","volume":"68","author":"A Desclaux","year":"2006","unstructured":"Desclaux A. Anthropologie des fi\u00e8vres h\u00e9morragiques virales. Bulletin Amades. 2006;68:1-4.3.","journal-title":"Bulletin Amades."},{"key":"6543_CR29","first-page":"1","volume":"11","author":"A Desclaux","year":"2015","unstructured":"Desclaux A, Sow K. \u00ab\u202fHumaniser\u202f\u00bb les soins dans l\u2019\u00e9pid\u00e9mie d\u2019Ebola\u202f? Les tensions dans la gestion du care et de la bios\u00e9curit\u00e9 dans le suivi des sujets contacts au S\u00e9n\u00e9gal. Anthropologie & Sant\u00e9. 2015;11:1.","journal-title":"Anthropologie & Sant\u00e9."},{"key":"6543_CR30","doi-asserted-by":"crossref","unstructured":"\u00d8stergaard L-R. Ebola vu de loin: les agents de la sant\u00e9 face au risque et \u00e0 l'incertitude dans les campagnes du Burkina Faso 2015; 11.","DOI":"10.4000\/anthropologiesante.1833"},{"key":"6543_CR31","unstructured":"Dean AG, Sullivan KM, Soe MM. OpenEpi: Open-Source Epidemiologic Statistics for Public Health, Version. www.OpenEpi.com, Updated 2013\/04\/06 https:\/\/www.openepi.com\/SampleSize\/SSPropor.htm Accessed 20 Apr 2021."},{"key":"6543_CR32","unstructured":"Association M\u00e9dicale Mondiale. D\u00e9claration d\u2019Helsinki de l\u2019AMM \u2013 principes \u00e9thiques applicables \u00e0 la recherche m\u00e9dicale impliquant des \u00eatres humains. https:\/\/www.wma.net\/fr\/policies-post\/declaration-dhelsinki-de-lamm-principes-ethiques-applicables-a-la-recherche-medicale-impliquant-des-etres-humains\/ Accessed 18 Apr 2021."},{"key":"6543_CR33","unstructured":"International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. J Postgrad Med. 2001;47(1):45\u201350. PMID: 11590294. https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf Accessed 20 Apr 2021."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06543-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06543-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06543-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T08:36:13Z","timestamp":1630658173000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06543-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6543"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06543-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"assertion":[{"value":"14 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project has been approved by the Ministry of Health (N\u00b0 2020-00952\/MS\/CAB\/INSP\/CM) and the national committee for health research of Burkina Faso (N\u00b0 2020-8-140). The study will be performed in compliance with the latest revised version of the Helsinki Declaration [], current legislation in Burkina Faso regarding clinical research, and the principles of Good Laboratory Practice and Good Clinical Practice []. Apart from emergency situations requiring the initiation of specific therapies, the investigators and their designated representatives commit to respecting every aspect of the study protocol, particularly concerning the collection of informed consent and the notification and follow-up of adverse events. All study participant to the study, will provide signed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"896"}}